ESPE Abstracts (2019) 92 P1-183

Diabetes and Insulin (1)

Study on the Mechanism of Metformin in Improving PGRN-Induced Insulin Resistance of 3T3-L1 Cell

Siqi Huang1, Liyang Liang1, Zhe Meng1, Lina Zhang1, Lele Hou1, Zulin Liu1, Hongshan Chen2


1Department of Pediatric, TheSun yat-sen memorial hospita of Sun-Yat sen University, Guangzhou, China. 2Department of Pediatric, The First Affiliated Hospital of Sun-Yat sen University, Guangzhou, China

To investigate the effect of metformin on the PERK-eIF2a pathway in PGRN - induced insulin - resistant cell model. METHODS: The 3T3-L1 Insulin-resistance cell model was constructed by dexamethasone and PGRN. Metformin was used to act on the cell model to screen out the optimal concentration group for reducing PGRN,The experiment was divided into the normal control group, dexamethasone group, and PGRN group. 4-PBA and metformin were used to act respectively.Western Blot was used to detect the expression of insulin signaling factor and PERK-eIF2a signaling factor in each group.RESULTS: After the action of PGRN and dexamethasone, p-Akt decreased,p-IRS-1, p-PERK, p-eIF2α increased while after the treatment with 4-PBA and metformin, p-Akt increased, p-IRS-1, p-PERK, p-eIF2α decreased.(P<0.05). CONCLUSION: Metformin acts on the insulin resistance cell model induced by PGRN, and its effect on PERK-eIF2a pathway and insulin pathway factor is consistent with that of endoplasmic reticulum stress inhibitor 4-PBA.It is suggested that metformin may reverse PGRN-induced insulin resistance by activating AMPK to inhibit the phosphorylation of PERK-eIF2α, an endoplasmic reticulum stress pathway.

Volume 92

58th Annual ESPE meeting

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.